Compare Stocks: ADAP, XLO, INKT, and IMMP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -10.5%	$0.09	$0.04 ▼ $0.36	$15.35M	2.49	57.14 million shs	49.26 million shs
IMMP Prima BioMed	$0.38 -1.1%	$0.40	$0.29 ▼ $3.53	$56.89M	2.25	128,071 shs	58,367 shs
INKT MiNK Therapeutics	$11.38 -3.7%	$11.28	$8.48 ▼ $16.98	$60.32M	0.48	8,715 shs	9,351 shs
XLO Xilio Therapeutics	$9.08 -1.2%	$9.08	$6.47 ▼ $12.74	$60.47M	-0.14	14,573 shs	5,896 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	-5.08%
IMMP Prima BioMed	-1.06%	-3.88%	-0.68%	-12.13%	-77.54%
INKT MiNK Therapeutics	-3.72%	-5.17%	+2.80%	+11.79%	-21.89%
XLO Xilio Therapeutics	-1.20%	-4.42%	+4.97%	+8.87%	-7.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -10.5%	$0.09	$0.04 ▼ $0.36	$15.35M	2.49	57.14 million shs	49.26 million shs
IMMP Prima BioMed	$0.38 -1.1%	$0.40	$0.29 ▼ $3.53	$56.89M	2.25	128,071 shs	58,367 shs
INKT MiNK Therapeutics	$11.38 -3.7%	$11.28	$8.48 ▼ $16.98	$60.32M	0.48	8,715 shs	9,351 shs
XLO Xilio Therapeutics	$9.08 -1.2%	$9.08	$6.47 ▼ $12.74	$60.47M	-0.14	14,573 shs	5,896 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	-5.08%
IMMP Prima BioMed	-1.06%	-3.88%	-0.68%	-12.13%	-77.54%
INKT MiNK Therapeutics	-3.72%	-5.17%	+2.80%	+11.79%	-21.89%
XLO Xilio Therapeutics	-1.20%	-4.42%	+4.97%	+8.87%	-7.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	1.00	Sell	N/A	N/A
IMMP Prima BioMed	2.00	Hold	$5.50	1,340.17% Upside
INKT MiNK Therapeutics	2.00	Hold	$35.00	207.56% Upside
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ADAP, XLO, INKT, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/12/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/10/2026	IMMP Prima BioMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/17/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/17/2026	IMMP Prima BioMed	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/15/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/27/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.09	N/A	N/A	$0.05 per share	1.16
IMMP Prima BioMed	$6.69M	8.41	N/A	N/A	$0.63 per share	0.61
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($2.75) per share	N/A
XLO Xilio Therapeutics	$43.77M	1.37	N/A	N/A	$10.98 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.65	N/A	N/A	N/A	-260.82%	-163.73%	-75.83%	N/A
IMMP Prima BioMed	-$39.78M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
INKT MiNK Therapeutics	-$12.49M	-$2.40	N/A	N/A	N/A	N/A	N/A	-92.37%	11/12/2026 (Estimated)
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest ADAP, XLO, INKT, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	H2 2026	IMMP Prima BioMed	-$0.0258	N/A	N/A	N/A	$11.73 million	N/A
8/13/2026	Q2 2026	INKT MiNK Therapeutics	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	N/A	1.52	1.29
IMMP Prima BioMed	N/A	2.97	N/A
INKT MiNK Therapeutics	N/A	1.23	1.23
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
IMMP Prima BioMed	2.32%
INKT MiNK Therapeutics	2.87%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
IMMP Prima BioMed	3.07%
INKT MiNK Therapeutics	20.40%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable
INKT MiNK Therapeutics	30	5.10 million	4.06 million	No Data
XLO Xilio Therapeutics	70	6.58 million	6.09 million	Not Optionable

ADAP, XLO, INKT, and IMMP Headlines

Recent News About These Companies

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Up 58.8% in July

August 18, 2026 | americanbankingnews.com

Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Expands By 58.8%

August 18, 2026 | marketbeat.com

Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS

August 12, 2026 | marketbeat.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics (XLO) Expected to Announce Earnings on Thursday

August 6, 2026 | marketbeat.com

Xilio Therapeutics (NASDAQ:XLO) Trading Down 0.2% - Here's Why

July 31, 2026 | marketbeat.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026 | globenewswire.com

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

April 1, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, XLO, INKT, and IMMP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Prima BioMed NASDAQ:IMMP

$0.38 0.00 (-1.06%)

Closing price 08/25/2026 03:53 PM Eastern

Extended Trading

$0.39 +0.01 (+1.86%)

As of 08/25/2026 05:00 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

MiNK Therapeutics NASDAQ:INKT

$11.38 -0.44 (-3.72%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$11.46 +0.08 (+0.75%)

As of 08/25/2026 04:10 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Xilio Therapeutics NASDAQ:XLO

$9.08 -0.11 (-1.20%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$9.04 -0.04 (-0.39%)

As of 08/25/2026 04:10 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAP, XLO, INKT, and IMMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAP, XLO, INKT, and IMMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAP, XLO, INKT, and IMMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, XLO, INKT, and IMMP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Prima BioMed NASDAQ:IMMP

MiNK Therapeutics NASDAQ:INKT

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAP, XLO, INKT, and IMMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAP, XLO, INKT, and IMMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAP, XLO, INKT, and IMMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, XLO, INKT, and IMMP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Prima BioMed NASDAQ:IMMP

MiNK Therapeutics NASDAQ:INKT

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools